Management of acute coronary syndromes with fondaparinux

about

A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient.Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review.

P2860

Q37112747-8CC13F44-A512-4221-999D-44F4EF1ADD85 Q42707980-9CDFD83C-9D25-40B7-8369-2A1C1490D491

P2860

Management of acute coronary syndromes with fondaparinux

Item

http://www.wikidata.org/entity/Q28219642

description

2007 nî lūn-bûn

@nan

2007 թուականին հրատարակուած գիտական յօդուած

@hyw

2007 թվականին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Management of acute coronary syndromes with fondaparinux

@ast

Management of acute coronary syndromes with fondaparinux

@en

Management of acute coronary syndromes with fondaparinux

@nl

type

Item

label

Management of acute coronary syndromes with fondaparinux

@ast

Management of acute coronary syndromes with fondaparinux

@en

Management of acute coronary syndromes with fondaparinux

@nl

prefLabel

Management of acute coronary syndromes with fondaparinux

@ast

Management of acute coronary syndromes with fondaparinux

@en

Management of acute coronary syndromes with fondaparinux

@nl

P1476

Management of acute coronary syndromes with fondaparinux

@en

P2093

Harm Wienbergen

http://www.w3.org/2001/XMLSchema#string

Uwe Zeymer

http://www.w3.org/2001/XMLSchema#string

P2860

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data

Pharmacodynamics, clinical indications, and adverse effects of heparin.

New anticoagulants: anti IIa vs anti Xa--is one better?

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise th

Fondaparinux: an update on new study results.

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.

Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

P304

321-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4467458

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17703640

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

P932

2293968

http://www.w3.org/2001/XMLSchema#string

Management of acute coronary syndromes with fondaparinux

about

P2860

P2860

Management of acute coronary syndromes with fondaparinux

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P407

P433

P478

P577

P698

P921

P932

P3181

P1433

P1476

P2093

P2860

P304

P31

P3181

P407

P433

P478

P577

P698

P921

P932